Last reviewed · How we verify
Innocell Autologous Cellular Immunotherapy — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Innocell Autologous Cellular Immunotherapy (Innocell Autologous Cellular Immunotherapy) — PhotonPharma, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Innocell Autologous Cellular Immunotherapy TARGET | Innocell Autologous Cellular Immunotherapy | PhotonPharma, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Innocell Autologous Cellular Immunotherapy CI watch — RSS
- Innocell Autologous Cellular Immunotherapy CI watch — Atom
- Innocell Autologous Cellular Immunotherapy CI watch — JSON
- Innocell Autologous Cellular Immunotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Innocell Autologous Cellular Immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/innocell-autologous-cellular-immunotherapy. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab